DFD-29

DRUG2 trials

Sponsors

Journey Medical Corporation

Conditions

Papulopustular Rosacea

Phase 3

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

CompletedNCT05296629

Journey Medical CorporationPapulopustular Rosacea

Start: 2022-03-14End: 2023-06-30Updated: 2024-12-03

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

CompletedNCT05343455

Journey Medical CorporationPapulopustular Rosacea

Start: 2022-03-29End: 2023-06-30Updated: 2024-12-03

Related Papers

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea

JAMA Dermatology2025-03-054 citations